201 related articles for article (PubMed ID: 36359312)
1. Theragnostic Radionuclide Pairs for Prostate Cancer Management:
Chhabra A; Thakur ML
Biomedicines; 2022 Nov; 10(11):. PubMed ID: 36359312
[TBL] [Abstract][Full Text] [Related]
2. Targeting Copper in Cancer Imaging and Therapy: A New Theragnostic Agent.
Capriotti G; Piccardo A; Giovannelli E; Signore A
J Clin Med; 2022 Dec; 12(1):. PubMed ID: 36615024
[TBL] [Abstract][Full Text] [Related]
3. Side effects of theragnostic agents currently employed in clinical practice.
Rizzo A; Annunziata S; Salvatori M
Q J Nucl Med Mol Imaging; 2021 Dec; 65(4):315-326. PubMed ID: 34881848
[TBL] [Abstract][Full Text] [Related]
4. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
5. PSMA Theranostics: Science and Practice.
Mokoala K; Lawal I; Lengana T; Kgatle M; Giesel FL; Vorster M; Sathekge M
Cancers (Basel); 2021 Aug; 13(15):. PubMed ID: 34359805
[TBL] [Abstract][Full Text] [Related]
6. Paving the way to personalized medicine: production of some promising theragnostic radionuclides at Brookhaven National Laboratory.
Srivastava SC
Semin Nucl Med; 2012 May; 42(3):151-63. PubMed ID: 22475424
[TBL] [Abstract][Full Text] [Related]
7. Nuclear Medicine and Cancer Theragnostics: Basic Concepts.
Zoi V; Giannakopoulou M; Alexiou GA; Bouziotis P; Thalasselis S; Tzakos AG; Fotopoulos A; Papadopoulos AN; Kyritsis AP; Sioka C
Diagnostics (Basel); 2023 Sep; 13(19):. PubMed ID: 37835806
[TBL] [Abstract][Full Text] [Related]
8. Theragnostic
Lee JY; Chae JH; Hur MG; Yang SD; Kong YB; Lee J; Ju JS; Choi PS; Park JH
Front Med (Lausanne); 2022; 9():889640. PubMed ID: 35665337
[No Abstract] [Full Text] [Related]
9. A prospective intra-individual comparison of [
Lawal IO; Mokoala KMG; Mahapane J; Kleyhans J; Meckel M; Vorster M; Ebenhan T; Rösch F; Sathekge MM
Eur J Nucl Med Mol Imaging; 2021 Jan; 48(1):134-142. PubMed ID: 32424485
[TBL] [Abstract][Full Text] [Related]
10. Theragnostics in primary and secondary liver tumors: the need for a personalized approach.
Filippi L; Braat AJ
Q J Nucl Med Mol Imaging; 2021 Dec; 65(4):353-370. PubMed ID: 34881847
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic Efficacy of a Bivalent Inhibitor of Prostate-Specific Membrane Antigen Labeled with
McInnes LE; Cullinane C; Roselt PD; Jackson S; Blyth BJ; van Dam EM; Zia NA; Harris MJ; Hicks RJ; Donnelly PS
J Nucl Med; 2021 Jun; 62(6):829-832. PubMed ID: 33067341
[TBL] [Abstract][Full Text] [Related]
12. New radiopharmaceutical agents for the treatment of castration-resistant prostate cancer.
Maffioli L; Florimonte L; Costa DC; Correia Castanheira J; Grana C; Luster M; Bodei L; Chinol M
Q J Nucl Med Mol Imaging; 2015 Dec; 59(4):420-38. PubMed ID: 26222274
[TBL] [Abstract][Full Text] [Related]
13. An international multi-center investigation on the accuracy of radionuclide calibrators in nuclear medicine theragnostics.
Saldarriaga Vargas C; Bauwens M; Pooters INA; Pommé S; Peters SMB; Segbers M; Jentzen W; Vogg A; van Velden FHP; Meyer Viol SL; Gotthardt M; Mottaghy FM; Wildberger JE; Covens P; Wierts R
EJNMMI Phys; 2020 Nov; 7(1):69. PubMed ID: 33226485
[TBL] [Abstract][Full Text] [Related]
14. PSMA Ligands for Radionuclide Imaging and Therapy of Prostate Cancer: Clinical Status.
Lütje S; Heskamp S; Cornelissen AS; Poeppel TD; van den Broek SA; Rosenbaum-Krumme S; Bockisch A; Gotthardt M; Rijpkema M; Boerman OC
Theranostics; 2015; 5(12):1388-401. PubMed ID: 26681984
[TBL] [Abstract][Full Text] [Related]
15. Elevated Serum Sialic Acid Levels Predict Prostate Cancer As Well As Bone Metastases.
Zhang C; Yan L; Song H; Ma Z; Chen D; Yang F; Fang L; Li Z; Li K; Li D; Yu N; Liu H; Xu Z
J Cancer; 2019; 10(2):449-457. PubMed ID: 30719139
[No Abstract] [Full Text] [Related]
16. Metabolomic characterization of human prostate cancer bone metastases reveals increased levels of cholesterol.
Thysell E; Surowiec I; Hörnberg E; Crnalic S; Widmark A; Johansson AI; Stattin P; Bergh A; Moritz T; Antti H; Wikström P
PLoS One; 2010 Dec; 5(12):e14175. PubMed ID: 21151972
[TBL] [Abstract][Full Text] [Related]
17. Aptamers as Theragnostic Tools in Prostate Cancer.
Cruz-Hernández CD; Rodríguez-Martínez G; Cortés-Ramírez SA; Morales-Pacheco M; Cruz-Burgos M; Losada-García A; Reyes-Grajeda JP; González-Ramírez I; González-Covarrubias V; Camacho-Arroyo I; Cerbón M; Rodríguez-Dorantes M
Biomolecules; 2022 Jul; 12(8):. PubMed ID: 36008950
[TBL] [Abstract][Full Text] [Related]
18. Clinical Theragnostic Potential of Diverse miRNA Expressions in Prostate Cancer: A Systematic Review and Meta-Analysis.
Jayaraj R; Raymond G; Krishnan S; Tzou KS; Baxi S; Ram MR; Govind SK; Chandramoorthy HC; Abu-Khzam FN; Shaw P
Cancers (Basel); 2020 May; 12(5):. PubMed ID: 32397507
[No Abstract] [Full Text] [Related]
19. Soft tissue metastasis of the penis detected by copper-64 labeled prostate-specific membrane antigen positron emission tomography (
Farhan C; Mirzaei S
Asia Ocean J Nucl Med Biol; 2021; 9(2):180-182. PubMed ID: 34250148
[TBL] [Abstract][Full Text] [Related]
20. Bibliometric analysis of the global research development of bone metastases in prostate cancer: A 22-year study.
Chen Y; Tang C; Shen Z; Peng S; Wu W; Lei Z; Zhou J; Li L; Lai Y; Huang H; Guo Z
Front Oncol; 2022; 12():947445. PubMed ID: 36237319
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
